The effect of apatinib combined with etoposide in maintenance therapy of extensive small cell lung cancer and its impact on levels of vascular endothelial growth factor and its receptor 2
Zhang Haili
Dong Guilan
Wang Zhiwu
Liu Lili
Lyu Lili
Abstract：Objective To explore the effect of apatinib combined with etoposide in maintenance therapy of extensive small cell lung cancer and its impact on levels of vascular endothelial growth factor(VEGF)and VEGF receptor 2(VEGFR2).Methods A total of 60 patients with extensive small cell lung cancer treated by standard radiotherapy and chemotherapy admitted to Tangshan People's Hospital,Hebei Province from January 2019 to February 2021 were enrolled.They were divided into control group and observation group according to the random number table method,with 30 patients in each group.The control group was given etoposide capsule for maintenance chemotherapy,and the observation group was treated with apatinib on the basis of the control group.The clinical effects of the two groups were evaluated.Serum levels of VEGF and VEGFR2 before and after treatment were compared between the two groups.Adverse reactions were recorded between the two groups.The survivals of the two groups were compared.Results The objective response rate and disease control rate of the observation group were higher than those of the control group[33.3％(10/30)vs 13.3％(4/30),60.0％(18/30)vs 36.7％(11/30)](both P＜0.05).After treatment,the levels of VEGF and VEGFR2 in both groups of patients were significantly lower than those before treatment,and the observation group was lower than the control group(all P＜0.05).There were no statistically significant differences in the occurrences of adverse reaction between the two groups(all P＞0.05).The 1-year and 2-year survival rates of the observation group were significantly higher than those of the control group(both P＜0.05).Conclusion The application of apatinib combined with etoposide in the maintenance treatment of extensive small cell lung cancer can inhibit the expression of tumor factors in patients'serum,and improve the clinical efficacy and survival rate of patients.The adverse reactions are tolerable.
Keywords：Extensive small cell lung cancerApatinibMaintenance therapySerum markers
Publication Date：2023-12-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 1798-1801 )